Semax vs Selank: Two Neuropeptides, Two Mechanisms
Semax and Selank are both synthetic neuropeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are studied for CNS-relevant mechanisms — but they are not alternatives for the same experiment. Semax targets BDNF upregulation and neuroprotective pathways; Selank modulates GABAergic tone and stress-response signaling. Understanding the distinction is essential for designing cognitively-focused research protocols.
Semax: ACTH/MSH Analogue and BDNF Upregulation
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the ACTH(4-10) sequence — the biologically active fragment of adrenocorticotropic hormone shared with alpha-MSH. It was developed in Russia in the 1980s and has been studied extensively in preclinical models for its effects on neurotrophic factor expression and neuroprotective signaling.
The primary mechanism studied in research is BDNF (brain-derived neurotrophic factor) upregulation. Semax has been shown in rodent models to increase BDNF mRNA expression in the hippocampus and frontal cortex, with downstream effects on TrkB receptor signaling, neuronal survival, and synaptic plasticity markers. Separately, Semax has been studied for its effects on VEGF (vascular endothelial growth factor) expression, with implications for models of ischemic injury and cerebrovascular research.
Semax does not directly bind the ACTH receptor (MC2R) at research-relevant concentrations — its structural analogy to ACTH(4-10) does not confer adrenal stimulation. Its CNS effects appear to be mediated through pathways involving enkephalinase inhibition and direct neurotrophic signaling rather than melanocortin receptor activation.
Selank: Tuftsin Analogue and GABAergic Modulation
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide comprising the immunopeptide tuftsin (Thr-Lys-Pro-Arg) extended with the Pro-Gly-Pro tripeptide. Tuftsin is an endogenous tetrapeptide derived from the heavy chain of IgG that plays a role in immune modulation. The extension was added to improve metabolic stability in research models.
Selank's most studied mechanism is GABAergic modulation. Research has demonstrated that Selank influences GABA-A receptor expression and benzodiazepine binding site activity in preclinical models, producing anxiolytic-like behavioral effects without the sedation or tolerance liability associated with classical benzodiazepines. This makes it a useful tool for studying the GABAergic system independently of direct benzodiazepine receptor agonism.
Selank has also been studied for interleukin-6 (IL-6) pathway modulation and enkephalinase inhibition — mechanisms it shares structurally with Semax. Some research suggests Selank upregulates BDNF as well, though this effect appears secondary to its primary GABAergic activity and less pronounced than the BDNF upregulation seen with Semax.
Stability and Half-Life Differences
Both peptides were engineered with the Pro-Gly-Pro extension specifically to resist enzymatic degradation by prolyl endopeptidase and other neuropeptidases, improving their stability in research models relative to the parent sequences.
- Semax: Relatively short half-life of approximately 20–30 minutes in plasma, though CNS effects persist longer due to the lag between peripheral administration and central BDNF expression changes. The BDNF upregulation observed in rodent studies is not immediate — it represents a transcriptional response that peaks hours after the peptide itself has cleared.
- Selank: Similar short plasma half-life, with GABAergic effects also persisting beyond the peptide's direct presence. The behavioral anxiolytic effects in preclinical models have been observed to outlast expected plasma concentration windows, suggesting downstream receptor adaptation.
For in vitro research models, the short half-life of both peptides means that timing and exposure duration are experimental variables that need to be controlled carefully when designing protocols.
Side-by-Side Comparison
| Semax | Selank | |
|---|---|---|
| Origin | ACTH(4-10) + Pro-Gly-Pro extension | Tuftsin (Thr-Lys-Pro-Arg) + Pro-Gly-Pro extension |
| Primary mechanism | BDNF upregulation, VEGF expression, neuroprotection | GABAergic modulation (GABA-A/benzodiazepine site), anxiolytic-like effects |
| Secondary mechanism | Enkephalinase inhibition, cerebrovascular effects | IL-6 pathway modulation, secondary BDNF upregulation |
| Receptor interaction | No direct ACTH receptor binding at research concentrations; acts via neurotrophic pathways | Indirect GABA-A modulation; no direct benzodiazepine binding |
| Half-life | ~20–30 min plasma; CNS effects last longer | ~20–30 min plasma; behavioral effects outlast plasma window |
| Research focus | Neuroprotection, ischemic models, BDNF/TrkB signaling, cognitive function | Anxiety models, GABAergic pharmacology, immune-CNS interface, stress biology |
| Research relationship | Complementary — different primary mechanisms, occasionally studied together for combined neurotrophic + anxiolytic effects | |
Research Applications
The different mechanisms of Semax and Selank open distinct but sometimes overlapping experimental directions:
- Neurotrophic factor research: Semax is the primary compound for studying BDNF upregulation and TrkB pathway activation. Models studying the BDNF/CREB/synaptic plasticity axis benefit from Semax as a reference BDNF-upregulating compound that works through a non-antidepressant mechanism.
- GABAergic pharmacology: Selank provides a unique research tool for studying GABA-A receptor modulation that is structurally unrelated to benzodiazepines, barbiturates, or neurosteroids. This makes it useful for isolating GABAergic contributions in mixed-mechanism anxiety models.
- Ischemia and cerebrovascular models: Semax has been studied in models of focal ischemia for its VEGF-mediated neuroprotective effects. Researchers studying cerebrovascular biology and post-ischemic recovery mechanisms have used Semax to probe neurovascular unit biology.
- Stress-response biology: Selank's IL-6 modulation and anxiolytic-like effects make it relevant to research on stress-response pathways, HPA axis biology, and the interface between immune activation and CNS function.